Aurobindo: US Tariffs ‘Not A Challenge’ For Now, Scouting For Biosimilars Tie-Ups
‘Entire’ GLP-1 Range Including Semaglutide To Be Launched
A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.
